Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of CCI-779 (Temsirolimus) and
bortezomib (Velcade), and the highest dose of this drug that can be given to people safely.
We will also be looking at how the combination of the two drugs may work against multiple
myeloma. CCI-779 (Temsirolimus) is a drug that appears to stop myeloma cells from growing.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Millennium Pharmaceuticals, Inc. Wyeth is now a wholly owned subsidiary of Pfizer